BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported (except for the Sentis Colorectal Cancer Panel for which a liquid biopsy version is still being developed).
BGI’s Cancer+ Discovery Panel is designed to identify all classes of actionable genomic alterations, including SNP, CNV, InDels and Fusions, across a total of 508 cancer-related genes. Results are supported by in depth mutation analysis and pharmacogenomics information relating to 102 cancer therapeutics approved by the FDA or currently undergoing clinical trials.
10 working days
Tissue - Fresh/Frozen tumor tissue, biopsy, FFPE, DNA + 5mL peripheral blood. ctDNA - Peripheral blood (10mL)
Target region capture, High-throughput sequencing
Ordering the BGI SENTIS™ Cancer+ Discovery Panel is easy.
Physician orders test
Blood or saliva sample collected
Sample shipped to BGI and analyzed
Results sent to physician